Please login to the form below

Not currently logged in

Webinar: AMNOG – One Year On

IMS Consulting Group and Booz & Co will discuss the changes to Germany’s pharma pricing system in the latest PMLiVE webinar on Monday 23 April

Germany Rhine

Once the first country in Europe to get innovative products, thanks to its favourable pricing structure, Germany used to be a popular launch destination for the pharmaceutical industry.

In December AstraZeneca's antiplatelet drug Brilique (ticagrelor) become the first drug to be backed under the country's new pricing assessment laws, but the introduction of AMNOG and the G-BA test has left many in pharma wondering if they would not be better off avoiding the country altogether.

On Monday 23 April at 12:30pm (UK time) PMLiVE's latest webinar, AMNOG - One Year, will feature speakers from IMS Consulting Group and Booz & Co discussing these important pricing changes and what they mean for pharma. To registor for the free webinar use the box below or click this link.


The webinar can be viewed on this page on Monday and then shortly after it finishes it will be available here in an archived form.

• PMLiVE's country report series also has more on the German healthcare market

20th April 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...